PGT-A (Preimplantation Genetic Testing for Aneuploidy) is the screening of embryos for chromosomal number abnormalities before transfer into the uterus. This is a crucial step in In Vitro Fertilization (IVF/ICSI) to increase the chance of a successful pregnancy and reduce the risk of miscarriage.
Typically, PGT-A detects abnormalities in all chromosome pairs, such as Trisomy (extra chromosome) and Monosomy(missing chromosome). However, traditional PGT-A technology faces several limitations, which led to the developmentof PGT-A Pixl, a more accurate technique.
Who is PGT-A Pixl suitable for ?
Women aged 35 years or older
Couples with a history of pregnancy affected by chromosomal abnormalities
Couples with a history of two or more miscarriages, due to chromosomal abnormalities or unexplained causes
Couples experiencing infertility with at least two failed embryo implantation attempts
Couples who require sex selection for medical reasons
Couples with known chromosomal abnormalities, such as chromosomal translocations
PGT-A Pixl: Sharper and Smarter Analysis
PGT-A Pixl is designed to overcome these limitations by analyzing thousands of single nucleotide polymorphisms (SNPs), which are small, naturally occurring variations at specific locations in the genome that serve as genetic markers.
This technique integrates two main analytical components:
1. Copy Number Analysis: Utilizes Next-generation sequencing (NGS) principles to measure the DNA Copy Number for each chromosome.
2. B-Allele Frequency (BAF) Analysis: Uses thousands of Single Nucleotide Polymorphisms (SNPs) to calculate the BAF, which reflects the genomic balance of DNA inherited from both parents.
Result Verification Mechanism:
The integration of Copy Number and BAF analysis provides a clearer and more accurate view:
Result Confirmation: PGT-A Pixl uses the BAF pattern to cross-verify the Copy Number results obtained from read counting. If both results are concordant, the diagnostic accuracy is significantly enhanced.
Reduced False Positives: Accurate verification using the correct BAF pattern helps reduce the reporting of false positives for Aneuploidy and Mosaicism.
Analytical Validation
Validation results show that PGT-A Pixl demonstrates high Concordance with accepted reference standards, accurately identifying complex conditions such as Triploidy, UPD, and Microdeletion, which confirms the robustness and reliability of this method.
In summary: PGT-A Pixl provides greater confidence to both clinicians and patients by delivering higher accuracy, reduced false positives, and expanded detection of complex abnormalities, allowing for the most effective selection of healthy embryos to maximize the chances of a successful pregnancy.
Comprehensive detection of complex abnormalities: Identifies abnormal ploidy and Uniparental Disomy (UPD), increasing the chance of successful implantation
Single-gene mutation detection: Expanded screening with Mini PGT-M for microdeletions and key genetic conditions such as thalassemia and hearing loss
High reliability: Ensures confidence in results through sample contamination detection
Accurate sex determination:Enabled by specifically designed target regions on the Y chromosome
